Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril

Journal of Pharmacy Practice

Volumn 26, Issue 4, 2013, Pages 382-388

  Norman, Johanna L ^a   Holmes, Whitney L ^b   Bell, William A ^c   Finks, Shannon W ^d  

^a LE BONHEUR CHILDREN S HOSPITAL   (United States)

^b BAPTIST MEMORIAL HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

cardiology; emergency medicine; internal medicine

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; AMFEBUTAMONE; AMLODIPINE; AMOXICILLIN PLUS CLAVULANIC ACID; BENZODIAZEPINE; CALCIUM; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; FLUMAZENIL; GLIPIZIDE; GUAIFENESIN; HYDROCHLOROTHIAZIDE; IBUPROFEN; IODIXANOL; LISINOPRIL; LORAZEPAM; METHOCARBAMOL; METHYLPREDNISOLONE; METOPROLOL TARTRATE; MOXIFLOXACIN; NALOXONE; PENICILLIN DERIVATIVE; PREDNISONE; RANITIDINE; SALBUTAMOL; SIMVASTATIN; UNINDEXED DRUG; VITAMIN D;

AFRICAN AMERICAN; AGED; ANAMNESIS; ANGIONEUROTIC EDEMA; ANXIETY DISORDER; APHASIA; ARTICLE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLAUSTROPHOBIA; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; FEMALE; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTENSIVE CARE UNIT; INTOXICATION; LUNG EMBOLISM; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PENICILLIN ALLERGY; RISK ASSESSMENT; SLEEP DISORDERED BREATHING; SMOKING; SORE THROAT; TRACHEOTOMY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; CHEMICALLY INDUCED;

AGED; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; LISINOPRIL;

EID: 84881148098     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012465990     Document Type: Article

References (42)

1. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005 ; 53 (3). 373-388
2. Mathelier-Fusade P. Drug-induced urticarias. Clin Rev Allergy Immunol. 2006 ; 30 (1). 19-23
3. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001 ; 24 (8). 599-606
4. Cherry DK, Woodwell DA, Rechsteiner EA. National ambulatory medical care survey: 2005 summary. Adv Data. 2007 ; (387). 1-39
5. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor associated angioedema. Immunol Allergy Clin North Am. 2006 ; 26 (4). 725-737
6. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cv treatment versus enalapril (OCTAVE) trial. Am J Hypertens. 2004 ; 17 (2). 103-111
7. Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996 ; 60 (1). 8-13
8. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol. 2007 ; 98 (1). 57-63
9. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol. 1999 ; 48 (6). 861-865
10. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004 ; 10 (4). 499-509
11. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005 ; 165 (14). 1637-1642
12. La Corte AL, Carter AM, Rice GI, et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor. Hum Mutat. 2011 ; 32 (11). 1326-1331
13. Hedner T, Samuelsson O, Lunde H, et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1992 ; 304 (6832). 941-946
14. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988 ; 260 (7). 967-970
15. Hameed MS, Patel AV, Bertino JS. Delayed angiotensin-converting enzyme inhibitor-induced angioedema. Hosp Physician. 2006 ; 42 (2). 33-36
16. Emanueli C, Grady EF, Madeddu P, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension. 1998 ; 31 (6). 1299-1304
17. Sulpizio AC, Pullen MA, Edwards RM, et al. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. J Pharmacol Exp Ther. 2004 ; 309 (3). 1141-1147
18. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004 ; 164 (8). 910-913
19. Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 1999 ; 44 (1-2). 21-25
20. Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010 ; 56 (3). 278-282
21. Brown N, Snowden M, Griffin M. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA. 1997 ; 278 (3). 232-233
22. Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 (15). 1547-1559
23. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 ; 362 (9386). 772-776
24. Sánchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000 ; 84 (1). 101-106
25. Quiralte J, Blanco C, Castillo R, et al. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol. 1996 ; 98 (3). 678-685
26. Pastorello EA, Zara C, Riario-Sforza GG, et al. Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy. 1998 ; 53 (9). 880-884
27. Berkes EA. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol. 2003 ; 24 (2). 137-148
28. Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004 ; 24 (3). 491-505
29. Strom BL, Carson JL, Morse ML, et al. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1987 ; 30 (10). 1142-1148
30. Asero R. Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update. Allergy Asthma Clin Immunol. 2007 ; 3 (1). 24-30
31. Andrzej Szczeklik A, Niżankowska-Mogilnicka E, Sanak M Middleton's Allergy: Principles and Practice. 7 th ed. Philadelphia, PA: Mosby; 2008:1237-1238. Adkinson NF Bochner BS Busse WW, ed. Philadelphia, PA: Mosby ; 2008: 1237-1238.
32. Banerji A, Oren E, Hesterberg P, et al. Ten-year study of causes of moderate to severe angioedema seen by an inpatient allergy/immunology consult service. Allergy Asthma Proc. 2008 ; 29 (1). 88-92
33. Campi P, Pichler WJ. Quinolone hypersensitivity. Curr Opin Allergy Clin Immunol. 2003 ; 3 (4). 275-281
34. Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol. 2004 ; 113 (1). 155-160
35. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001 ; 21 (10 pt 2). 253S - 272S
36. Avelox (moxifloxacin hydrochloride) prescribing information. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc. http://www.avelox.com/html/pdf/avelox- prescribing.pdf. Accessed November 9, 2010.
37. Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf. 2006 ; 29 (11). 1087-1100
38. Aranda A, Mayorga C, Ariza A, et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy. 2011 ; 66 (2). 247-254
39. Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf. 2007 ; 30 (8). 705-713
40. Simons FE. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol. 2009 ; 124 (4). 625-636
41. Weldon D. Differential diagnosis of angioedema. Immunol Allergy Clin N Am. 2006 ; 26 (4). 603-613
42. Schwartz LB, Yunginger JW, Miller J, et al. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989 ; 83 (5). 1551-1555